Company Overview
Company Type: Private Company
Website: alpha-cancer.com
Number of Employees: -
Year Founded: 2008
Total Amount Raised (CAD mm)†: 12.49
Total Rounds of Funding**:2
Latest Post-Money Valuation ($ mm) 29.19
Latest Pre-Money Valuation ($ mm) 20.85
† This number reflects the estimated value of the total new money raised through private placement rounds.
** This value is an estimate of the total number of funding rounds this company has received.


Business Description
Alpha Cancer Technologies Inc., a clinical-stage biotechnology company, develops drugs for oncology and auto-immune disease indications. Its products include alpha fetoprotein, a human protein produced by the embryo during foetal development; an immunotherapy platform; and a targeted chemotherapy platform. The company offers non-covalently bound chemotherapy (paclitaxel and thapsigargin) and chemically linked chemotherapy, such as maytansine. It uses recombinant human alpha-fetoprotein to selectively target cancer cells by delivering toxic chemotherapeutic agents exclusively to these cells. Alpha Cancer Technologies Inc. was incorporated in 2008 and is based in Toronto, Canada.


Financial Information (Currency: CAD, in mm)
Total Revenue
-
Operating Income
-
Total Assets
-
Gross Profit
-
EBITDA
-
Total Debt
-
Net Income
-
Estimated Number of Employees
-
Net Debt
-
* Hover over data point numbers for date and source.

Key Professionals
Name
Title
Sherman, Igor A.
Founder, Chief Executive Officer and President 

Key Board Members
Name
Title
Potts, Richard
Chairman
Chabursky, Borys 
Director
Morgan, Christopher W.
Director
Puritt, Jeffrey D.
Director


Primary Industry Classification
Biotechnology


Primary Office Location
MaRS Center South Tower 200-101 College Street | Toronto, ON | M5G 1L7 | Canada
Phone: 416-826-6626   Fax: 416-782-3944

Current and Pending Investors
Investor
Initial Investment Date
Stake Type
Current Stake Amount
Round(s)
Innovation Grade Ventures
-
Unknown
-
-


Company Notes
No Company Notes exist.


Strategy Notes
No Strategy Notes exist.


Last 5 Transactions
Announced Date
Closed Date
Transaction Type
Role
Target
Buyer/Investors
Sellers
Size($mm)
Feb-19-2014
Cancelled
Merger/Acquisition
Buyer
Bradmer Pharmaceuticals Inc. (nka:Galaxy Digital Holdings Ltd. (TSX:GLXY))
Alpha Cancer Technologies Inc.
Highbridge Capital Management, LLC,Evermore Investments, LLC
-
Feb-18-2014
-
Private Placement
Target
Alpha Cancer Technologies Inc.


8.34
Feb-19-2013
Feb-19-2013
Private Placement
Target
Alpha Cancer Technologies Inc.


2.07
* denotes that the relationship is proprietary


Last 5 Key Developments
Date
Event Type
Headline
May-31-2023
Product-Related Announcements
Alpha Cancer Technologies Inc. Presents New Data from ACT-903, an AFP-Maytansine Conjugate, in Online Publication at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting
Apr-06-2023
Product-Related Announcements
Alpha Cancer Technologies Inc. Publishes Pre-Clinical Study Results in Cancer Cell International
Oct-30-2018
Company Conference Presentations
Alpha Cancer Technologies Inc. Presents at The NYC Oncology Investor Conference, Oct-30-2018 12:05 PM
May-09-2018
Company Conference Presentations
Alpha Cancer Technologies Inc. Presents at NYC Oncology Investor Conference 2018, May-09-2018 11:30 AM
Oct-17-2017
Product-Related Announcements
Alpha Cancer Technologies Inc. announces Results of a Study of Act-101 in the Treatment of Inflammatory Bowel Disease


Advisors
Private Placement Advisors
Echelon Wealth Partners Inc.


Last 10 Investment Research Documents
Contributor
Analyst
Date/Time
Company
Headline
Type
Pages
GlobalData

Sep 15, 2023 03:48 AM
Alpha Cancer Technologies Inc.
Alpha Cancer Technologies Inc - Pharmaceuticals and Healthcare Product Pipeline Summary
Reports
34
GlobalData

Sep 14, 2023 09:29 PM
Alpha Cancer Technologies Inc.
Alpha Cancer Technologies Inc
Reports
47
GlobalData

Jun 19, 2023 05:39 AM
Alpha Cancer Technologies Inc.
Alpha Cancer Technologies Inc
Reports
47
GlobalData

Jun 09, 2023 06:58 AM
Alpha Cancer Technologies Inc.
Alpha Cancer Technologies Inc - Pharmaceuticals and Healthcare Product Pipeline Summary
Reports
34
GlobalData

Mar 15, 2023 01:40 AM
Alpha Cancer Technologies Inc.
Alpha Cancer Technologies Inc
Reports
45
GlobalData

Mar 10, 2023 06:55 AM
Alpha Cancer Technologies Inc.
Alpha Cancer Technologies Inc - Pharmaceuticals and Healthcare Product Pipeline Summary
Reports
32
GlobalData

Dec 15, 2022 01:51 AM
Alpha Cancer Technologies Inc.
Alpha Cancer Technologies Inc
Reports
45
GlobalData

Dec 10, 2022 02:47 AM
Alpha Cancer Technologies Inc.
Alpha Cancer Technologies Inc - Pharmaceuticals and Healthcare Product Pipeline Summary
Reports
32
GlobalData

Sep 21, 2022 07:53 AM
Alpha Cancer Technologies Inc.
Alpha Cancer Technologies Inc
Reports
45
GlobalData

Sep 15, 2022 06:24 AM
Alpha Cancer Technologies Inc.
Alpha Cancer Technologies Inc - Pharmaceuticals and Healthcare Product Pipeline Summary
Reports
32


S&P Global Ratings Credit Ratings
No S&P Global Ratings Credit Ratings data available. 


News Headlines
No News is currently available for the selected sources.


Company Coverage
This company is not on any Coverage List.

Key Board Members Details
Name
Title
Phone
Fax
Email
Potts, Richard
Chairman
416-826-6626
416-782-3944
rpotts@alphacancer.com
Chabursky, Borys 
Director
416-826-6626
416-782-3944

Morgan, Christopher W.
Director
416-777-4710
416-782-3944
christopher.morgan@skadden.com
Puritt, Jeffrey D.
Director
416-826-6626
416-782-3944

* denotes that the relationship is proprietary

Key Executives and Professionals Details
Name
Title
Phone
Fax
Email
Sherman, Igor A.
Founder, Chief Executive Officer and President 
416-826-6626
416-782-3944
isherman@alphacancer.com
* denotes that the relationship is proprietary

S&P Credit Ratings and Research provided by 
No content (including ratings, credit-related analyses and data, valuations, model, software or other application or output therefrom) or any part thereof (Content) may be modified, reverse engineered, reproduced or distributed in any form by any means, or stored in a database or retrieval system, without the prior written permission of S&P Global Market Intelligence or its affiliates (collectively, S&P Global). The Content shall not be used for any unlawful or unauthorized purposes. S&P Global and any third-party providers, as well as their directors, officers, shareholders, employees or agents (collectively S&P Global Parties) do not guarantee the accuracy, completeness, timeliness or availability of the Content. S&P Global Parties are not responsible for any errors or omissions (negligent or otherwise), regardless of the cause, for the results obtained from the use of the Content, or for the security or maintenance of any data input by the user. The Content is provided on an "as is" basis. S&P GLOBAL PARTIES DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING, BUT NOT LIMITED TO, ANY WARRANTIES OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE OR USE, FREEDOM FROM BUGS, SOFTWARE ERRORS OR DEFECTS, THAT THE CONTENT’S FUNCTIONING WILL BE UNINTERRUPTED OR THAT THE CONTENT WILL OPERATE WITH ANY SOFTWARE OR HARDWARE CONFIGURATION. In no event shall S&P Global Parties be liable to any party for any direct, indirect, incidental, exemplary, compensatory, punitive, special or consequential damages, costs, expenses, legal fees, or losses (including, without limitation, lost income or lost profits and opportunity costs or losses caused by negligence) in connection with any use of the Content even if advised of the possibility of such damages.

Credit-related and other analyses, including ratings, and statements in the Content are statements of opinion as of the date they are expressed and not statements of fact. S&P Global Market Intelligence’s opinions, analyses and rating acknowledgment decisions (described below) are not recommendations to purchase, hold, or sell any securities or to make any investment decisions, and do not address the suitability of any security. S&P Global Market Intelligence assumes no obligation to update the Content following publication in any form or format. The Content should not be relied on and is not a substitute for the skill, judgment and experience of the user, its management, employees, advisors and/or clients when making investment and other business decisions. S&P Global Market Intelligence does not act as a fiduciary or an investment advisor except where registered as such. While S&P Global Market Intelligence has obtained information from sources it believes to be reliable, S&P Global Market Intelligence does not perform an audit and undertakes no duty of due diligence or independent verification of any information it receives.

S&P Global keeps certain activities of its divisions separate from each other in order to preserve the independence and objectivity of their respective activities. As a result, certain divisions of S&P Global may have information that is not available to other S&P Global divisions. S&P Global has established policies and procedures to maintain the confidentiality of certain non-public information received in connection with each analytical process.

S&P Global Ratings does not contribute to or participate in the creation of credit scores generated by S&P Global Market Intelligence. Lowercase nomenclature is used to differentiate S&P Global Market Intelligence PD credit model scores from the credit ratings issued by S&P Global Ratings.

S&P Global may receive compensation for its ratings and certain analyses, normally from issuers or underwriters of securities or from obligors. S&P Global reserves the right to disseminate its opinions and analyses. S&P Global's public ratings and analyses are made available on its Web sites, www.standardandpoors.com (free of charge), and www.capitaliq.com (subscription), and may be distributed through other means, including via S&P Global publications and third-party redistributors. Additional information about our ratings fees is available at www.standardandpoors.com/usratingsfees.
Regulatory News Service data provided by 
